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LETTER TO THE EDITOR 
 
Hepatitis B virus (HBV) infection is a major public 
health problem affecting more than 250 million people 
globally. Chronic hepatitis B (CHB) is a result of an 
acute, unresolved infection, that, overtime, may lead to 
cirrhosis and its complications such as liver failure and 
hepatocellular carcinoma [1]. In the last 15 years, sever-
al inhibitors of HBV polymerase, namely nucleos(t)ide 
analogues (NAs), have been developed and introduced 
in clinical practice, allowing long term suppression of 
HBV replication (virological response) and alanine ami-
notransferase (ALT) normalization (biochemical re-
sponse) [2]. Hepatitis B surface antigen (HBsAg) loss 
and seroconversion to anti-HBs has been traditionally 
considered the final goal of antiviral treatment (func-
tional cure). However, a complete cure could be 
achieved only with the physical elimination of HBV co-
valently-closed-circular DNA (cccDNA) which acts as 
template for all viral transcriptions and is responsible 
for long lasting viral persistence [3]. Currently, novel 
approaches aiming at HBV cccDNA elimination or in-
activation are under evaluation at a preclinical level [3]. 
However, the possibility to measure intrahepatic HBV 
cccDNA is limited by liver biopsy availability and the 
lack of sensitive standardized PCR methods. 
Hepatitis B core-related antigen (HBcrAg) is a novel se-
rum biomarker combining the antigenic reactivity re-
sulting from hepatitis B e antigen (HBeAg), HBV core 
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antigen, and a 22 kDa core-related protein (p22cr) 
mainly found in HBV empty particles [4,5]. It has been 
reported that HBcrAg levels varied significantly among 
the four natural phases of HBV infection showing high 
predictive performance for distinguishing between 
HBeAg-negative inactive/quiescent carrier and HBeAg-
negative hepatitis-patients (area under the curve [AUC] 
= 0.931) and for the discrimination between immune 
tolerant and immune clearance phases (AUC = 0.704) 
[6]. 
Interestingly, a significant correlation between HBcrAg 
and intrahepatic HBV cccDNA has been reported [7-9]. 
Suzuki et al., investigating the correlation between 
HBcrAg and intrahepatic HBV cccDNA in a cohort of 
Japanese CHB patients, found a positive correlation be-
tween the two parameters (r = 0.692, p < 0.001). In ad-
dition, a significant correlation between HBcrAg and in-
trahepatic HBV cccDNA was also observed in patients 
that experienced HBsAg negativization (r = 0.482,         
p = 0.006), suggesting a potential role of HBcrAg also 
in subjects with occult HBV infection [7]. More recent-
ly, Matsuzaki et al. also reported a correlation between 
HBcrAg and HBV cccDNA levels (r = 0.616,                
p < 0.001) in patients undergoing liver transplant [8]. 
After excluding preoperative state samples from analy-
sis, HBcrAg remained significantly correlated to HBV 
cccDNA (r = 0.402, p = 0.046). Furthermore, HBcrAg 
and HBV cccDNA values showed similar kinetics dur-
ing pre- and post-transplantation, highlighting HBcrAg 
reliability as a surrogate biomarker for HBV cccDNA 
[8]. Finally, a large-scale study including 305 liver bi-
opsies and corresponding serum samples collected from 
138 NAs-treated patients pointed out a median HBcrAg 
reduction at ≥ 6 years of therapy comparable to the 
magnitude of HBV cccDNA decay [9]. HBcrAg was 
strongly correlated with intrahepatic HBV cccDNA        
(r = 0.70, p < 0.0001). According to HBeAg status, 
HBcrAg was significantly correlated to HBV cccDNA 
levels both in the 133 HBeAg-positive patients               
(r = 0.66, p < 0.0001) and in the 172 -negative patients 
(r = 0.45, p < 0.0001). Moreover, analyzing 130 sam-
ples of HBV DNA-negative patients receiving antiviral 
therapy, authors observed that HBcrAg was still detect-
able in 101 of them, being significantly correlated with 
HBV cccDNA levels (r = 0.42, p < 0.0001) [8]. 
 
 
CONCLUSION 
 
Since the quantification of HBV cccDNA levels will be 
important in clinical trials evaluating novel treatment 
concepts to cure HBV infection, its relationship with 
HBcrAg quantification renders the latter a reliable non-
invasive approach useful for monitoring intrahepatic vi-
rological status. 
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